NCT00324675View on ClinicalTrials.gov

Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2010

Conditions
Type 2 DiabetesOvert Diabetic Nephropathy
Interventions
DRUG

Rosiglitazone

4 mg tablets, bid, 12 months

DRUG

Placebo

2 tablets per day

Trial Locations (1)

01307

University hospital Dresden, Dresden

All Listed Sponsors
lead

Technische Universität Dresden

OTHER

NCT00324675 - Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy | Biotech Hunter | Biotech Hunter